Sylvain Sandy, Silvain Christine, Bainaud Matthieu, Kerforne Thomas, Masson Regnault Marie
Dermatology, Poitiers University Hospital, Poitiers, FRA.
Gastroenterology, Poitiers University Hospital, Poitiers, FRA.
Cureus. 2025 Aug 6;17(8):e89494. doi: 10.7759/cureus.89494. eCollection 2025 Aug.
Risankizumab (RZB) is a humanized monoclonal antibody that selectively targets interleukin-23 (IL-23). It has proven particularly effective in treating psoriasis, a common chronic inflammatory skin disease. However, its use remains poorly documented in certain populations, including patients with a history of solid organ transplantation or recent/active malignancy. We present a case of successful and well-tolerated treatment with RZB over an 18-month follow-up period in a patient with multiple comorbidities, including liver transplantation, recurrent hepatocellular carcinoma (HCC) with adrenal metastases, and severe chronic kidney disease.
瑞莎珠单抗（RZB）是一种选择性靶向白细胞介素-23（IL-23）的人源化单克隆抗体。它已被证明在治疗银屑病（一种常见的慢性炎症性皮肤病）方面特别有效。然而，在某些人群中，包括有实体器官移植史或近期/活动性恶性肿瘤的患者，其使用情况的记录仍然很少。我们报告了一例患有多种合并症的患者，包括肝移植、复发性肝细胞癌（HCC）伴肾上腺转移和严重慢性肾脏病，在18个月的随访期内成功且耐受性良好地接受了RZB治疗的病例。
